Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
21.2.2023 17:11:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltrating tumors and crossing blood-brain barriers. Additionally, nanobodies generally have longer CDR3 regions which enables them to recognize hidden epitopes better. Due to their simpler structure, nanobodies are more stable and easier to produce and engineer, making them ideal building blocks for complex modalities such as cell therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).
After several years of endeavor, Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMab™. RenNano mouse possesses full human heavy chain variable regions and can produce heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, i.e., nanobodies, do not require in vitro humanization to develop drugs. Our research has shown that RenNano mouse can generate robust immune responses after immunizations by different antigens. HCAbs generated from the RenNano mouse have highly diverse CDR3 sequences and can recognize many epitopes with nM-level high affinities. In vitro and in vivo experiments have shown that RenNano-derived antibodies have favorable biological functions.
Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”. The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale nanobody development abilities with collaborators’ expertise in nanobody-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.
“We believe that with the ability to rapidly develop fully human nanobodies against selected targets, the ‘Nano 100 Project’ will provide our global partners with more diverse and better nanobody building blocks to accelerate the development of novel drugs,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Meanwhile, it is also an important supplement to Biocytogen’s Project Integrum.”
About RenNano®
Biocytogen's proprietary fully human nanobody generating mouse, RenNano, is one of the most comprehensive fully human antibody platforms in the world. Nanobody sequences generated from RenNano mice have the highest possible diversity and do not require antibody humanization, which saves time and cost and reduces the risk of failure during later stages of drug development. Additionally, compared to natural HCAb-producing species like camelids, mice are easier to breed and immunize, making them suitable for developing HCAbs on a large scale.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005554/en/
Contact information
Biocytogen
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Names Dan McNamara Chief Customer Officer16.9.2026 20:13:00 EEST | Press release
Brightfin, the leading platform for total spend intelligence in enterprise IT, today announced that Dan McNamara has joined the company as Chief Customer Officer (CCO). The appointment comes as Brightfin extends its platform into a broader vision of financial truth and operational clarity across the entire enterprise technology stack, and as more IT and finance leaders turn to Brightfin to make sense of fast-growing, fragmented spend across cloud, mobile, and emerging AI tooling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916064892/en/ Dan McNamara, CCO of Brightfin McNamara has built his career on meeting increasingly complex customer expectations. Twice, he has joined a customer organization in the middle of rapid growth and left it with a stronger customer base. As Chief Customer Officer at Apryse, he helped grow annual recurring revenue from $40 million to $250 million while the company completed more than 15 acqu
Jazwares Partners With Sanrio to Expand Its Hello Kitty and Friends Range to EMEA16.9.2026 19:00:00 EEST | Press release
Jazwares, one of the world’s leading toy companies, today announced a licensing agreement with Sanrio GmbH, extending Jazwares successful Hello Kitty and Friends toy line to Europe, the Middle East, and Africa (EMEA). The agreement will bring Sanrio’s beloved Hello Kitty and Friends characters to even more fans in the region through playful, imaginative products designed for kids and collectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916913201/en/ Jazwares partners with Sanrio to expand its Hello Kitty and Friends range to EMEA Available across key EMEA markets, the collection of trendy plush and figures, playsets, vehicles, and seasonal items reimagines Hello Kitty alongside fan-favorite friends including Cinnamoroll, Kerokerokeroppi, Pompompurin, Tuxedosam, My Melody, Kuromi, Pochacco, Bad Badtz-Maru, and Little Twin Stars. “Hello Kitty and Friends commands a truly multi-generational, global fanbase, cementing i
Schneider Electric Concludes Innovation Summit Middle East & Africa, Highlights Energy Intelligence as the Next Phase of the Energy Transition16.9.2026 16:30:00 EEST | Press release
As AI, electrification and industrial expansion reshape energy demand across the Middle East and Africa, Schneider Electric today concluded Innovation Summit Middle East & Africa by positioning energy intelligence as the next phase of the energy transition - where infrastructure becomes more connected, resilient and software-defined. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916593883/en/ Walid Sheta, President, MEA Zone at Schneider Electric, releasing the company's 2026 Industrial AI in CPG Study for the UAE, at Schneider Electric Innovation Summit MEA (Photo: AETOSWire) Held at ADNEC in Abu Dhabi, the two-day summit convened over 2,500 attendees, including government leaders, industry analysts, customers, partners, students, and media, under the theme ‘Advancing Energy Tech to Power Intelligence and Resilience.’ Industry leaders explored how electrification, AI-ready data centers, cybersecurity, and digital innova
The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision16.9.2026 15:23:00 EEST | Press release
Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916231950/en/ Outdoor relaxation area at Jayasom Wellness Resort AMAALA, where serene design and sea-facing spaces create a setting for rest and renewal. Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal. “As we launch the first Jayasom globally, we are bringing a new dimension to AMAALA’s wellness offering. Its dedicated, all-inclusive wellness retreats combine contemporary, evidence-based practices with Arab and East
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 15:01:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916811892/en/ Figure Legend: Representative images of intact ex vivo human hair follicles challenged with DHT 100 nM and stimulated with finasteride 600 nM (positive control) or RLS-1496 2000 nM at Days 0 and 6. RLS-1496 has already demonstrated efficacy in clinical trials for actinic keratoses and aging skin, and other skin conditions such as psoriasis and atopic dermatitis, generating novel human evidence demonstrating the dual SenoAdaptive mec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom